Pb-dotam (Not yet branded)
Other Medications
Description
Pb-dotam is a radioactive compound used as part of CEA-PRIT (Pretargeted Radioimmunotherapy) for metastatic colorectal cancer. This agent consists of lead-212 (Pb-212) conjugated to a DOTAM chelator, designed to deliver targeted radiation therapy to CEA-expressing tumor cells. It is specifically utilized in patients with microsatellite stable (MSS) metastatic colorectal cancer as part of a two-step pretargeting approach.
Mechanism of Action
Pb-dotam works through a pretargeted radioimmunotherapy mechanism where an anti-CEA antibody is first administered to bind to CEA proteins overexpressed on colorectal cancer cells. The Pb-dotam compound is then delivered and binds to the pre-positioned antibody via biotin-streptavidin interactions. The lead-212 isotope emits high-energy alpha particles that cause DNA damage and cell death in CEA-positive tumor cells while minimizing radiation exposure to healthy tissues.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.